## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## **SCHEDULE 14A INFORMATION**

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed	by the	e Registrant [X]	Filed by a Party other than the Registrant [ ]					
Chec	k the	appropriate box:						
[ ] [ ] [X]	Con Defin	Preliminary Proxy Statement  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  Definitive Proxy Statement  Definitive Additional Materials  Soliciting Material Pursuant to Section 240.14a-12						
			SINTX TECHNOLOGIES, INC. (Name of Registrant as Specified in Its Charter)					
			Commission File Number: 001-33624					
			Not Applicable (Name of Persons Filing Proxy Statement If Other Than the Registrant)					
Payn	nent of	f Filing Fee (Check th	e appropriate box):					
[X]	No fee required.							
[ ]	Fee	Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.						
	1)	Title of each class o	of securities to which transaction applies:					
	2)	Aggregate number of	of securities to which transaction applies:					
	3)	Per unit price or oth state how it was dete	ner underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and ermined):					
	4)	Proposed maximum	aggregate value of transaction:					
	5)	Total fee paid:						
]	Fee paid previously with preliminary materials.							
[ ]	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.							
	1)	Amount Previously	Paid:					
	2)	Form, Schedule or F	Registration Statement No.:					
	3)	Filing Party:						
	4)	Date Filed:						



April 29, 2019

Dear Stockholder,

You may already be aware that the company's 2019 Annual Meeting of Stockholders has been adjourned to May 23, 2019 at 10:00 am Mountain Time, at the company's headquarters at 1855 West 2100 South, Salt Lake City, Utah 84119 with respect to Proposal No. 2 (the "Proposal"), a proposal to approve an amendment to the Company's Restated Certificate of Incorporation to effectuate a reverse stock split of our issued and outstanding shares of Common Stock at a ratio of between 1-for-2 and 1-for-30.

The meeting was adjourned to allow additional time to solicit proxies from our stockholders on the Proposal. Stockholders have thus far strongly supported the Proposal. At the time of the meeting, approximately 60% of the shares that had been voted on the Proposal had been voted in its favor. However, the favorable votes were less than the absolute majority of all outstanding shares needed for approval. As we stated in the proxy statement previously delivered to you, we only intend to implement the reverse stock split if needed to maintain our listing on The NASDAQ Capital Market. If the proposal is not approved, then our listing on The NASDAQ Capital Market will be in jeopardy.

According to our records, your vote has not been received. Regardless of how many shares you own, your vote is extremely important, and your shares cannot be voted unless you give your specific instructions. We ask that you please take a moment to authorize a proxy to vote today by following the instructions on the enclosed voting form. If you need assistance in voting your shares or for general inquiries, please contact our proxy solicitation agent D.F. King & Co., Inc. toll-free at (866) 207-2239. The Company's Board has unanimously recommended that stockholders vote **FOR Proposal 2**.

A fuller description of the Proposal is contained in the proxy statement dated March 25, 2019 which is available free of charge on our Investor Relations website at https://ir.sintx.com/annual-shareholder-materials.

We want to thank you again for voting and for your continued interest in SINTX Technologies. If you have any questions, please feel free to contact us at 1-801-839-3502.

Sincerely,

B. Sonny Bal, MD JD MBA PhD

Chairman of the Board and CEO